Details of the Drug Formulations

General Information of Drug (ID: DMT6AM2)

Drug Name
Ozanimod Drug Info
Synonyms
1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Non-small-cell lung cancer 2C25.Y Phase 3 [2]
Ulcerative colitis DD71 Phase 3 [3]
Crohn disease DD70 Phase 2 [3]
Cross-matching ID
PubChem CID
52938427
CAS Number
1306760-87-1
TTD ID
D07EDB
ACDINA ID
D01311

Full List of Drug Formulations Containing This Drug

Ozanimod 0.23 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F24103 Colloidal Silicon Dioxide; Croscarmellose Sodium; Magnesium Stearate; Microcrystalline Cellulose; Black Iron Oxide; Gelatin; Red Iron Oxide; Titanium Dioxide; Yellow Iron Oxide
------------------------------------------------------------------------------------
Ozanimod 0.46 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F24104 Colloidal Silicon Dioxide; Croscarmellose Sodium; Magnesium Stearate; Microcrystalline Cellulose; Black Iron Oxide; Gelatin; Red Iron Oxide; Titanium Dioxide; Yellow Iron Oxide
------------------------------------------------------------------------------------
Ozanimod 0.92 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F24105 Colloidal Silicon Dioxide; Croscarmellose Sodium; Magnesium Stearate; Microcrystalline Cellulose; Black Iron Oxide; Gelatin; Red Iron Oxide; Titanium Dioxide; Yellow Iron Oxide
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 ClinicalTrials.gov (NCT02294058) Phase 3 Study of RPC1063 in Relapsing MS. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)